Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer
Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone.
Gespeichert in:
| Veröffentlicht in: | The New England journal of medicine 2023-06, Vol.388 (22), p.2058-2070 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2070 |
|---|---|
| container_issue | 22 |
| container_start_page | 2058 |
| container_title | The New England journal of medicine |
| container_volume | 388 |
| creator | Turner, Nicholas C. Oliveira, Mafalda Howell, Sacha J. Dalenc, Florence Cortes, Javier Gomez Moreno, Henry L. Hu, Xichun Jhaveri, Komal Krivorotko, Petr Loibl, Sibylle Morales Murillo, Serafin Okera, Meena Park, Yeon Hee Sohn, Joohyuk Toi, Masakazu Tokunaga, Eriko Yousef, Samih Zhukova, Lyudmila de Bruin, Elza C. Grinsted, Lynda Schiavon, Gaia Foxley, Andrew Rugo, Hope S. |
| description | Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone. |
| doi_str_mv | 10.1056/NEJMoa2214131 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11335038</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2821641260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c534t-3270c3fa759a676741a50c01f1b640d31e5bee37507b080e0ee5b3a6c849398e3</originalsourceid><addsrcrecordid>eNp1kV1LHDEUhkNRdN166a0MiODNtCdz8jFzJbrYarGtiL0OmexZzbIzWZPZBe_6H_oP_SWddVWq0NyEnDw8nJeXsT0OnzhI9fnH2bfvwRYFFxz5BzbgEjEXAtQGGwAUZS50hdtsJ6Up9IeLaottoy6kqrQasNORnfulTRQ7X2e-zc5DbEJL2TU5mnchPv7-cxWS7_ySspPx0raOxtlpJJu6bLR6xY9sc2JniXaf7yH79eXsZnSeX_78ejE6ucydRNHlWGhwOLFaVlZppQW3EhzwCa-VgDFykjURagm6hhIIqB-gVa4UFVYl4ZAdr73zRd3Q2FHbRTsz8-gbGx9MsN68_Wn9nbkNS8M5ogQse8PRsyGG-wWlzjQ-OZrNbEthkUxRFlwJXijo0YN36DQsYtvne6JQVyvrkOVrysWQUqTJ6zYczKoe86aent__N8Ir_dJHDxyugaZJpqVp8x_RX8BNljM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2821379113</pqid></control><display><type>article</type><title>Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ProQuest Central UK/Ireland</source><source>New England Journal of Medicine</source><creator>Turner, Nicholas C. ; Oliveira, Mafalda ; Howell, Sacha J. ; Dalenc, Florence ; Cortes, Javier ; Gomez Moreno, Henry L. ; Hu, Xichun ; Jhaveri, Komal ; Krivorotko, Petr ; Loibl, Sibylle ; Morales Murillo, Serafin ; Okera, Meena ; Park, Yeon Hee ; Sohn, Joohyuk ; Toi, Masakazu ; Tokunaga, Eriko ; Yousef, Samih ; Zhukova, Lyudmila ; de Bruin, Elza C. ; Grinsted, Lynda ; Schiavon, Gaia ; Foxley, Andrew ; Rugo, Hope S.</creator><creatorcontrib>Turner, Nicholas C. ; Oliveira, Mafalda ; Howell, Sacha J. ; Dalenc, Florence ; Cortes, Javier ; Gomez Moreno, Henry L. ; Hu, Xichun ; Jhaveri, Komal ; Krivorotko, Petr ; Loibl, Sibylle ; Morales Murillo, Serafin ; Okera, Meena ; Park, Yeon Hee ; Sohn, Joohyuk ; Toi, Masakazu ; Tokunaga, Eriko ; Yousef, Samih ; Zhukova, Lyudmila ; de Bruin, Elza C. ; Grinsted, Lynda ; Schiavon, Gaia ; Foxley, Andrew ; Rugo, Hope S. ; CAPItello-291 Study Group</creatorcontrib><description>Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone.</description><identifier>ISSN: 0028-4793</identifier><identifier>ISSN: 1533-4406</identifier><identifier>EISSN: 1533-4406</identifier><identifier>DOI: 10.1056/NEJMoa2214131</identifier><identifier>PMID: 37256976</identifier><language>eng</language><publisher>United States: Massachusetts Medical Society</publisher><subject>Adverse events ; AKT protein ; AKT1 protein ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Aromatase ; Aromatase Inhibitors - adverse effects ; Aromatase Inhibitors - therapeutic use ; Breast Cancer ; Breast Neoplasms - drug therapy ; Breast Neoplasms - pathology ; Cancer therapies ; Cyclin-dependent kinase 4 ; Cyclin-dependent kinases ; Diarrhea ; Disease prevention ; Double-Blind Method ; Double-blind studies ; Endocrine therapy ; Estrogens ; Female ; Fulvestrant ; Fulvestrant - adverse effects ; Fulvestrant - therapeutic use ; Hematology ; Humans ; Kinases ; Magnetic resonance imaging ; Male ; Metastasis ; Mutation ; Neoplasm Recurrence, Local - drug therapy ; Oncology ; Placebos ; Post-menopause ; Proto-Oncogene Proteins c-akt ; PTEN protein ; Quality of life ; Receptor, ErbB-2 ; Regulatory approval ; Survival ; Treatments in Oncology ; Tumors ; Womens health</subject><ispartof>The New England journal of medicine, 2023-06, Vol.388 (22), p.2058-2070</ispartof><rights>Copyright © 2023 Massachusetts Medical Society. All rights reserved.</rights><rights>Copyright © 2023 Massachusetts Medical Society.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c534t-3270c3fa759a676741a50c01f1b640d31e5bee37507b080e0ee5b3a6c849398e3</citedby><cites>FETCH-LOGICAL-c534t-3270c3fa759a676741a50c01f1b640d31e5bee37507b080e0ee5b3a6c849398e3</cites><orcidid>0000-0002-2303-2764 ; 0000-0001-7623-1583</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.nejm.org/doi/pdf/10.1056/NEJMoa2214131$$EPDF$$P50$$Gmms$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2821379113?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,777,781,882,2746,2747,26084,27905,27906,52363,54045,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37256976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Turner, Nicholas C.</creatorcontrib><creatorcontrib>Oliveira, Mafalda</creatorcontrib><creatorcontrib>Howell, Sacha J.</creatorcontrib><creatorcontrib>Dalenc, Florence</creatorcontrib><creatorcontrib>Cortes, Javier</creatorcontrib><creatorcontrib>Gomez Moreno, Henry L.</creatorcontrib><creatorcontrib>Hu, Xichun</creatorcontrib><creatorcontrib>Jhaveri, Komal</creatorcontrib><creatorcontrib>Krivorotko, Petr</creatorcontrib><creatorcontrib>Loibl, Sibylle</creatorcontrib><creatorcontrib>Morales Murillo, Serafin</creatorcontrib><creatorcontrib>Okera, Meena</creatorcontrib><creatorcontrib>Park, Yeon Hee</creatorcontrib><creatorcontrib>Sohn, Joohyuk</creatorcontrib><creatorcontrib>Toi, Masakazu</creatorcontrib><creatorcontrib>Tokunaga, Eriko</creatorcontrib><creatorcontrib>Yousef, Samih</creatorcontrib><creatorcontrib>Zhukova, Lyudmila</creatorcontrib><creatorcontrib>de Bruin, Elza C.</creatorcontrib><creatorcontrib>Grinsted, Lynda</creatorcontrib><creatorcontrib>Schiavon, Gaia</creatorcontrib><creatorcontrib>Foxley, Andrew</creatorcontrib><creatorcontrib>Rugo, Hope S.</creatorcontrib><creatorcontrib>CAPItello-291 Study Group</creatorcontrib><title>Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer</title><title>The New England journal of medicine</title><addtitle>N Engl J Med</addtitle><description>Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone.</description><subject>Adverse events</subject><subject>AKT protein</subject><subject>AKT1 protein</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Aromatase</subject><subject>Aromatase Inhibitors - adverse effects</subject><subject>Aromatase Inhibitors - therapeutic use</subject><subject>Breast Cancer</subject><subject>Breast Neoplasms - drug therapy</subject><subject>Breast Neoplasms - pathology</subject><subject>Cancer therapies</subject><subject>Cyclin-dependent kinase 4</subject><subject>Cyclin-dependent kinases</subject><subject>Diarrhea</subject><subject>Disease prevention</subject><subject>Double-Blind Method</subject><subject>Double-blind studies</subject><subject>Endocrine therapy</subject><subject>Estrogens</subject><subject>Female</subject><subject>Fulvestrant</subject><subject>Fulvestrant - adverse effects</subject><subject>Fulvestrant - therapeutic use</subject><subject>Hematology</subject><subject>Humans</subject><subject>Kinases</subject><subject>Magnetic resonance imaging</subject><subject>Male</subject><subject>Metastasis</subject><subject>Mutation</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Oncology</subject><subject>Placebos</subject><subject>Post-menopause</subject><subject>Proto-Oncogene Proteins c-akt</subject><subject>PTEN protein</subject><subject>Quality of life</subject><subject>Receptor, ErbB-2</subject><subject>Regulatory approval</subject><subject>Survival</subject><subject>Treatments in Oncology</subject><subject>Tumors</subject><subject>Womens health</subject><issn>0028-4793</issn><issn>1533-4406</issn><issn>1533-4406</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp1kV1LHDEUhkNRdN166a0MiODNtCdz8jFzJbrYarGtiL0OmexZzbIzWZPZBe_6H_oP_SWddVWq0NyEnDw8nJeXsT0OnzhI9fnH2bfvwRYFFxz5BzbgEjEXAtQGGwAUZS50hdtsJ6Up9IeLaottoy6kqrQasNORnfulTRQ7X2e-zc5DbEJL2TU5mnchPv7-cxWS7_ySspPx0raOxtlpJJu6bLR6xY9sc2JniXaf7yH79eXsZnSeX_78ejE6ucydRNHlWGhwOLFaVlZppQW3EhzwCa-VgDFykjURagm6hhIIqB-gVa4UFVYl4ZAdr73zRd3Q2FHbRTsz8-gbGx9MsN68_Wn9nbkNS8M5ogQse8PRsyGG-wWlzjQ-OZrNbEthkUxRFlwJXijo0YN36DQsYtvne6JQVyvrkOVrysWQUqTJ6zYczKoe86aent__N8Ir_dJHDxyugaZJpqVp8x_RX8BNljM</recordid><startdate>20230601</startdate><enddate>20230601</enddate><creator>Turner, Nicholas C.</creator><creator>Oliveira, Mafalda</creator><creator>Howell, Sacha J.</creator><creator>Dalenc, Florence</creator><creator>Cortes, Javier</creator><creator>Gomez Moreno, Henry L.</creator><creator>Hu, Xichun</creator><creator>Jhaveri, Komal</creator><creator>Krivorotko, Petr</creator><creator>Loibl, Sibylle</creator><creator>Morales Murillo, Serafin</creator><creator>Okera, Meena</creator><creator>Park, Yeon Hee</creator><creator>Sohn, Joohyuk</creator><creator>Toi, Masakazu</creator><creator>Tokunaga, Eriko</creator><creator>Yousef, Samih</creator><creator>Zhukova, Lyudmila</creator><creator>de Bruin, Elza C.</creator><creator>Grinsted, Lynda</creator><creator>Schiavon, Gaia</creator><creator>Foxley, Andrew</creator><creator>Rugo, Hope S.</creator><general>Massachusetts Medical Society</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BEC</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>K0Y</scope><scope>LK8</scope><scope>M0R</scope><scope>M0T</scope><scope>M1P</scope><scope>M2M</scope><scope>M2O</scope><scope>M2P</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2303-2764</orcidid><orcidid>https://orcid.org/0000-0001-7623-1583</orcidid></search><sort><creationdate>20230601</creationdate><title>Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer</title><author>Turner, Nicholas C. ; Oliveira, Mafalda ; Howell, Sacha J. ; Dalenc, Florence ; Cortes, Javier ; Gomez Moreno, Henry L. ; Hu, Xichun ; Jhaveri, Komal ; Krivorotko, Petr ; Loibl, Sibylle ; Morales Murillo, Serafin ; Okera, Meena ; Park, Yeon Hee ; Sohn, Joohyuk ; Toi, Masakazu ; Tokunaga, Eriko ; Yousef, Samih ; Zhukova, Lyudmila ; de Bruin, Elza C. ; Grinsted, Lynda ; Schiavon, Gaia ; Foxley, Andrew ; Rugo, Hope S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c534t-3270c3fa759a676741a50c01f1b640d31e5bee37507b080e0ee5b3a6c849398e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adverse events</topic><topic>AKT protein</topic><topic>AKT1 protein</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Aromatase</topic><topic>Aromatase Inhibitors - adverse effects</topic><topic>Aromatase Inhibitors - therapeutic use</topic><topic>Breast Cancer</topic><topic>Breast Neoplasms - drug therapy</topic><topic>Breast Neoplasms - pathology</topic><topic>Cancer therapies</topic><topic>Cyclin-dependent kinase 4</topic><topic>Cyclin-dependent kinases</topic><topic>Diarrhea</topic><topic>Disease prevention</topic><topic>Double-Blind Method</topic><topic>Double-blind studies</topic><topic>Endocrine therapy</topic><topic>Estrogens</topic><topic>Female</topic><topic>Fulvestrant</topic><topic>Fulvestrant - adverse effects</topic><topic>Fulvestrant - therapeutic use</topic><topic>Hematology</topic><topic>Humans</topic><topic>Kinases</topic><topic>Magnetic resonance imaging</topic><topic>Male</topic><topic>Metastasis</topic><topic>Mutation</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Oncology</topic><topic>Placebos</topic><topic>Post-menopause</topic><topic>Proto-Oncogene Proteins c-akt</topic><topic>PTEN protein</topic><topic>Quality of life</topic><topic>Receptor, ErbB-2</topic><topic>Regulatory approval</topic><topic>Survival</topic><topic>Treatments in Oncology</topic><topic>Tumors</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Turner, Nicholas C.</creatorcontrib><creatorcontrib>Oliveira, Mafalda</creatorcontrib><creatorcontrib>Howell, Sacha J.</creatorcontrib><creatorcontrib>Dalenc, Florence</creatorcontrib><creatorcontrib>Cortes, Javier</creatorcontrib><creatorcontrib>Gomez Moreno, Henry L.</creatorcontrib><creatorcontrib>Hu, Xichun</creatorcontrib><creatorcontrib>Jhaveri, Komal</creatorcontrib><creatorcontrib>Krivorotko, Petr</creatorcontrib><creatorcontrib>Loibl, Sibylle</creatorcontrib><creatorcontrib>Morales Murillo, Serafin</creatorcontrib><creatorcontrib>Okera, Meena</creatorcontrib><creatorcontrib>Park, Yeon Hee</creatorcontrib><creatorcontrib>Sohn, Joohyuk</creatorcontrib><creatorcontrib>Toi, Masakazu</creatorcontrib><creatorcontrib>Tokunaga, Eriko</creatorcontrib><creatorcontrib>Yousef, Samih</creatorcontrib><creatorcontrib>Zhukova, Lyudmila</creatorcontrib><creatorcontrib>de Bruin, Elza C.</creatorcontrib><creatorcontrib>Grinsted, Lynda</creatorcontrib><creatorcontrib>Schiavon, Gaia</creatorcontrib><creatorcontrib>Foxley, Andrew</creatorcontrib><creatorcontrib>Rugo, Hope S.</creatorcontrib><creatorcontrib>CAPItello-291 Study Group</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>eLibrary</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection</collection><collection>New England Journal of Medicine</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Healthcare Administration Database</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The New England journal of medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Turner, Nicholas C.</au><au>Oliveira, Mafalda</au><au>Howell, Sacha J.</au><au>Dalenc, Florence</au><au>Cortes, Javier</au><au>Gomez Moreno, Henry L.</au><au>Hu, Xichun</au><au>Jhaveri, Komal</au><au>Krivorotko, Petr</au><au>Loibl, Sibylle</au><au>Morales Murillo, Serafin</au><au>Okera, Meena</au><au>Park, Yeon Hee</au><au>Sohn, Joohyuk</au><au>Toi, Masakazu</au><au>Tokunaga, Eriko</au><au>Yousef, Samih</au><au>Zhukova, Lyudmila</au><au>de Bruin, Elza C.</au><au>Grinsted, Lynda</au><au>Schiavon, Gaia</au><au>Foxley, Andrew</au><au>Rugo, Hope S.</au><aucorp>CAPItello-291 Study Group</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer</atitle><jtitle>The New England journal of medicine</jtitle><addtitle>N Engl J Med</addtitle><date>2023-06-01</date><risdate>2023</risdate><volume>388</volume><issue>22</issue><spage>2058</spage><epage>2070</epage><pages>2058-2070</pages><issn>0028-4793</issn><issn>1533-4406</issn><eissn>1533-4406</eissn><abstract>Among persons with breast cancer previously treated with hormonal therapy, the AKT pathway inhibitor capivasertib when added to fulvestrant significantly prolonged progression-free survival as compared with fulvestrant alone.</abstract><cop>United States</cop><pub>Massachusetts Medical Society</pub><pmid>37256976</pmid><doi>10.1056/NEJMoa2214131</doi><tpages>13</tpages><orcidid>https://orcid.org/0000-0002-2303-2764</orcidid><orcidid>https://orcid.org/0000-0001-7623-1583</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0028-4793 |
| ispartof | The New England journal of medicine, 2023-06, Vol.388 (22), p.2058-2070 |
| issn | 0028-4793 1533-4406 1533-4406 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11335038 |
| source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ProQuest Central UK/Ireland; New England Journal of Medicine |
| subjects | Adverse events AKT protein AKT1 protein Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Aromatase Aromatase Inhibitors - adverse effects Aromatase Inhibitors - therapeutic use Breast Cancer Breast Neoplasms - drug therapy Breast Neoplasms - pathology Cancer therapies Cyclin-dependent kinase 4 Cyclin-dependent kinases Diarrhea Disease prevention Double-Blind Method Double-blind studies Endocrine therapy Estrogens Female Fulvestrant Fulvestrant - adverse effects Fulvestrant - therapeutic use Hematology Humans Kinases Magnetic resonance imaging Male Metastasis Mutation Neoplasm Recurrence, Local - drug therapy Oncology Placebos Post-menopause Proto-Oncogene Proteins c-akt PTEN protein Quality of life Receptor, ErbB-2 Regulatory approval Survival Treatments in Oncology Tumors Womens health |
| title | Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T05%3A58%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Capivasertib%20in%20Hormone%20Receptor%E2%80%93Positive%20Advanced%20Breast%20Cancer&rft.jtitle=The%20New%20England%20journal%20of%20medicine&rft.au=Turner,%20Nicholas%20C.&rft.aucorp=CAPItello-291%20Study%20Group&rft.date=2023-06-01&rft.volume=388&rft.issue=22&rft.spage=2058&rft.epage=2070&rft.pages=2058-2070&rft.issn=0028-4793&rft.eissn=1533-4406&rft_id=info:doi/10.1056/NEJMoa2214131&rft_dat=%3Cproquest_pubme%3E2821641260%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2821379113&rft_id=info:pmid/37256976&rfr_iscdi=true |